Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cullinan Therapeutics Inc
(NQ:
CGEM
)
15.55
-0.67 (-4.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cullinan Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
April 20, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Overview Of Value Stocks In The Healthcare Sector
April 10, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Cullinan Oncology
March 27, 2023
Via
Benzinga
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
March 27, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
5 Value Stocks In The Healthcare Sector
January 09, 2023
Via
Benzinga
Insiders Buy Around $15M Of 2 Stocks
June 06, 2022
Although the Dow Jones dropped by around 350 points on Friday, there were a few notable insider trades.
Via
Benzinga
Short Volatility Alert: Cullinan Oncology
May 17, 2022
On Monday, shares of Cullinan Oncology, Inc. (NASDAQ: CGEM) experienced volatile short activity. After the activity, the stock price went up at 2.45% to $10.88. The overall...
Via
Benzinga
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
March 14, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
February 27, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
February 18, 2023
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of...
Via
Talk Markets
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
February 13, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
February 02, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
January 24, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
5 Value Stocks To Watch In The Healthcare Sector
January 02, 2023
Via
Benzinga
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
November 02, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
November 01, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
October 25, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
A Look Into Healthcare Sector Value Stocks
October 03, 2022
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 17, 2022
Via
Benzinga
Mid-Afternoon Market Update: Nasdaq Down 200 Points; Dutch Bros Shares Plunge
May 12, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 200 points on Thursday.
Via
Benzinga
90 Biggest Movers From Yesterday
May 13, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
May 12, 2022
Via
Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
May 12, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 102.6% to $0.1580 after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.